PHASE II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE PLUS RECOMBINANT HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR (rhG-CSF) IN THE TREATMENT OF FOLLICULAR LOW-GRADE NON-HODGKIN'S LYMPHOMA
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Cyclophosphamide (Primary) ; Filgrastim (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 31 Mar 2011 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
- 31 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2005 New trial record.